Close

Exelixis, Inc. (EXEL) Reports Positive Results from Phase 3 Trial of Cobimetinib

September 29, 2014 7:12 AM EDT Send to a Friend
Exelixis Inc. (NASDAQ: EXEL) today announced the positive results from coBRIM, the phase 3 pivotal trial conducted by Exelixis’ collaborator ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login